Development of a Bispecific Antibody Targeting KRAS Mutations
A research group including the National Institutes of Biomedical Innovation, Health and Nutrition has developed a bispecific antibody targeting a neoantigen derived from the KRAS G12V mutation found in pancreatic and colorectal cancers. The antibody guides T cells to cancer cells, enabling them to attack the cancer cells. It is compatible with multiple HLA types and is expected to have potential applications in treating some patients with pancreatic and colorectal cancers.